Cargando…

RAC1 Activation as a Potential Therapeutic Option in Metastatic Cutaneous Melanoma

Metastasis is a complex process by which cancer cells escape from the primary tumor to colonize distant organs. RAC1 is a member of the RHO family of small guanosine triphosphatases that plays an important role in cancer migration, invasion, angiogenesis and metastasis. RAC1 activation has been rela...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colón-Bolea, Paula, García-Gómez, Rocío, Casar, Berta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615836/ https://www.ncbi.nlm.nih.gov/pubmed/34827551 http://dx.doi.org/10.3390/biom11111554

Ejemplares similares

RAC1 induces nuclear alterations through the LINC complex to enhance melanoma invasiveness
por: Colón-Bolea, Paula, et al.
Publicado: (2020)

Defined spatiotemporal features of RAS-ERK signals dictate cell fate in MCF-7 mammary epithelial cells
por: Herrero, Ana, et al.
Publicado: (2016)

In Cellulo Evaluation of the Therapeutic Potential of NHC Platinum Compounds in Metastatic Cutaneous Melanoma
por: Charignon, Elsa, et al.
Publicado: (2020)

The Rac inhibitor HV-107 as a potential therapeutic for metastatic breast cancer
por: Crespo, Grace Velez, et al.
Publicado: (2023)

Amelanotic metastatic cutaneous melanoma
por: Mendes, Marcela Sena Teixeira, et al.
Publicado: (2013)

Metastatic Cutaneous Melanoma of the Gallbladder
por: Patel, Dhruvan, et al.
Publicado: (2017)

Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience
por: Gibbons, Ivana Lameiras, et al.
Publicado: (2018)

Lymphatic Transport Efficiency Determines Metastatic Potential of Cutaneous Melanoma
por: Holder, Ashley M., et al.
Publicado: (2020)

Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma
por: Karagianni, Fani, et al.
Publicado: (2022)

FMRP ligand circZNF609 destabilizes RAC1 mRNA to reduce metastasis in acral melanoma and cutaneous melanoma
por: Shang, Qingfeng, et al.
Publicado: (2022)

SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas
por: Zhu, Eliot Y., et al.
Publicado: (2022)

Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms
por: Marei, Hadir, et al.
Publicado: (2016)

Rac-GEF/Rac Signaling and Metastatic Dissemination in Lung Cancer
por: Cooke, Mariana, et al.
Publicado: (2020)

Real-world evidence for option value in metastatic melanoma
por: Wong, William B, et al.
Publicado: (2021)

Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells
por: Baugher, Paige J, et al.
Publicado: (2005)

RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation
por: Casar, Berta, et al.
Publicado: (2018)

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
por: Chan, Wei Yen, et al.
Publicado: (2021)

Topical Diphencyprone as an Effective Treatment for Cutaneous Metastatic Melanoma
por: Kim, Young Jin
Publicado: (2012)

Metastatic breast disease from cutaneous malignant melanoma()
por: Moschetta, Marco, et al.
Publicado: (2013)

Diffuse cutaneous melanosis: rare complication of metastatic melanoma
por: do Amaral, Ana Cristina Vervloet, et al.
Publicado: (2017)

Management of metastatic cutaneous melanoma: updates in clinical practice
por: Schvartsman, Gustavo, et al.
Publicado: (2019)

Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Identification of four genes associated with cutaneous metastatic melanoma
por: Ji, Chen, et al.
Publicado: (2020)

The Genetic Basis of Dormancy and Awakening in Cutaneous Metastatic Melanoma
por: Janowska, Agata, et al.
Publicado: (2022)

Screening and identification of potential prognostic biomarkers in metastatic skin cutaneous melanoma by bioinformatics analysis
por: Sheng, Zufeng, et al.
Publicado: (2020)

Treatment options for metastatic melanoma in solid organ transplant recipients
por: Shin, Thuzar M., et al.
Publicado: (2015)

A novel combinatorial treatment option for metastatic uveal melanoma
por: Shneor, Dudi, et al.
Publicado: (2018)

Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma
por: Heijkants, Renier, et al.
Publicado: (2017)

Pin1–FOXM1 inhibitors: a potential therapeutic for metastatic melanoma?
por: de Keizer, Peter LJ
Publicado: (2016)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
por: Stagno, Anna, et al.
Publicado: (2021)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma
por: Raymond, Jérémy H., et al.
Publicado: (2022)

Catastrophic brain metastatic lesions in a child with cutaneous melanoma
por: Vide, Ana Teresa, et al.
Publicado: (2011)

Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities
por: Lemech, Charlotte, et al.
Publicado: (2012)

The Identification of Prognostic and Metastatic Alternative Splicing in Skin Cutaneous Melanoma
por: Huang, Runzhi, et al.
Publicado: (2022)

From the Cochrane Library: Systemic Treatments for Metastatic Cutaneous Melanoma
por: Hamp, Austin, et al.
Publicado: (2021)

Metastatic disease from uveal melanoma: treatment options and future prospects
por: Carvajal, Richard D, et al.
Publicado: (2017)

Editorial on Special Issue “Advances and Novel Treatment Options in Metastatic Melanoma”
por: Carè, Alessandra, et al.
Publicado: (2022)

SPARC Controls Melanoma Cell Plasticity through Rac1
por: Salvatierra, Edgardo, et al.
Publicado: (2015)

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
por: Jain, Rohit K, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fm3osj08n2pcni092dt2m0m22q